This could be due to the absence of PIK3CA mutation in half of colorectal cancer patients, and the frequent co-occurrence of KRAS pathogenic variants with PIK3CA mutations, leading to a shorter reported PFS and potentially reduced activity against PIK3CA inhibitors. The gene discussed is KRAS; the disease is colorectal cancer.